Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders

Westerberg, 2020, Epidemiology of myasthenia gravis in Sweden 2006–2016, Brain Behav, 10, 10.1002/brb3.1819

Breiner, 2016, Epidemiology of myasthenia gravis in Ontario, Canada, Neuromuscul Disord, 26, 41, 10.1016/j.nmd.2015.10.009

Gattellari, 2012, A national epidemiological study of myasthenia gravis in Australia, Eur J Neurol, 19, 1413, 10.1111/j.1468-1331.2012.03698.x

Martinka, 2018, Epidemiology of myasthenia gravis in Slovakia in the years 1977–2015, Neuroepidemiology, 50, 153, 10.1159/000487886

Park, 2016, Incidence and prevalence of myasthenia gravis in Korea: a population-based study using the National Health Insurance claims database, J Clin Neurol, 12, 340, 10.3988/jcn.2016.12.3.340

Zieda, 2018, A nationwide epidemiological study of myasthenia gravis in Latvia, Eur J Neurol, 25, 519, 10.1111/ene.13535

Huijbers, 2022, Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders, Lancet Neurol, 21, 163, 10.1016/S1474-4422(21)00357-4

Verschuuren, 2022, Advances and ongoing research in the treatment of autoimmune neuormuscular junction disorders, Lancet Neurol, 21, 189, 10.1016/S1474-4422(21)00463-4

Zisimopoulou, 2014, A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis, J Autoimmun, 52, 139, 10.1016/j.jaut.2013.12.004

Gasperi, 2014, Anti-agrin autoantibodies in myasthenia gravis, Neurology, 82, 1976, 10.1212/WNL.0000000000000478

Zhang, 2014, Autoantibodies to agrin in myasthenia gravis patients, PLoS One, 9

Gilhus, 2015, Myasthenia gravis: subgroup classification and therapeutic strategies, Lancet Neurol, 14, 1023, 10.1016/S1474-4422(15)00145-3

Titulaer, 2011, Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS, J Clin Oncol, 29, 902, 10.1200/JCO.2010.32.0440

Gregersen, 2012, Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08, Ann Neurol, 72, 927, 10.1002/ana.23691

Maniaol, 2012, Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population, PLoS One, 7, 10.1371/journal.pone.0036603

Cortes-Vicente, 2020, Clinical and therapeutic features of myasthenia gravis in adults based on age at onset, Neurology, 94, e1171, 10.1212/WNL.0000000000008903

Maddison, 2019, A prospective study of the incidence of myasthenia gravis in the East Midlands of England, Neuroepidemiology, 53, 93, 10.1159/000500268

Hendricks, 2019, Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study, Am J Ophthalmol, 205, 99, 10.1016/j.ajo.2019.04.017

Sipila, 2019, Hospital admission and prevalence trends of adult myasthenia gravis in Finland in 2004–2014: a retrospective national registry study, J Neurol Sci, 407, 10.1016/j.jns.2019.116520

Lotan, 2020, Incidence of AChR Ab-positive myasthenia gravis in Israel: a population-based study, Acta Neurol Scand, 142, 66, 10.1111/ane.13239

Santos, 2016, Epidemiology of myasthenia gravis in northern Portugal: frequency estimates and clinical epidemiological distribution of cases, Muscle Nerve, 54, 413, 10.1002/mus.25068

Mombaur, 2015, Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa, Muscle Nerve, 51, 533, 10.1002/mus.24348

Boldingh, 2015, Geographical distribution of myasthenia gravis in northern Europe: results from a population-based study from two countries, Neuroepidemiology, 44, 221, 10.1159/000431036

Pedersen, 2013, Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996–2009, Eur J Neurol, 20, 309, 10.1111/j.1468-1331.2012.03850.x

Dragin, 2016, Estrogen-mediated downregulation of AIRE influences sexual dimorphism in autoimmune diseases, J Clin Invest, 126, 1525, 10.1172/JCI81894

Popperud, 2017, Juvenile myasthenia gravis in Norway: a nationwide epidemiological study, Eur J Paediatr Neurol, 21, 312, 10.1016/j.ejpn.2016.09.001

Huda, 2016, Characteristics of acetylcholine-receptor-antibody-negative myasthenia gravis in a South African cohort, Muscle Nerve, 54, 1023, 10.1002/mus.25154

Li, 2018, Clinical characteristics of AChRAb and MuSKAb double seropositive myasthenia gravis patients, Clin Neurol Neurosurg, 172, 69, 10.1016/j.clineuro.2018.06.041

Lu, 2020, AChR myasthenia gravis switching to MuSK or double antibody positive myasthenia gravis in two children and literature review, Neuromuscul Disord, 30, 534, 10.1016/j.nmd.2020.03.012

Park, 2018, Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: autoantibody profiles and clinical features, PLoS One, 13

Rivner, 2018, Muscle-specific tyrosine kinase and myasthenia gravis owing to other antibodies, Neurol Clin, 36, 293, 10.1016/j.ncl.2018.01.004

Pevzner, 2012, Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis, J Neurol, 259, 427, 10.1007/s00415-011-6194-7

Wirtz, 2004, The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands, Neurology, 63, 397, 10.1212/01.WNL.0000130254.27019.14

Maddison, 2017, Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome, Neurology, 88, 1334, 10.1212/WNL.0000000000003794

de Meel, 2019, Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis, Neuromuscul Disord, 29, 664, 10.1016/j.nmd.2019.07.006

Verschuuren, 2010, Clinical aspects of myasthenia explained, Autoimmunity, 43, 344, 10.3109/08916931003602130

Liu, 2019, Myasthenic crisis treated in a Chinese neurological intensive care unit: clinical features, mortality, outcomes, and predictors of survival, BMC Neurol, 19, 172, 10.1186/s12883-019-1384-5

Neumann, 2020, Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases, Neurology, 94, e299, 10.1212/WNL.0000000000008688

Sivadasan, 2019, Comorbidities and long-term outcomes in a cohort with myasthenic crisis: experiences from a tertiary care center, Ann Indian Acad Neurol, 22, 464, 10.4103/aian.AIAN_197_19

Li, 2018, Generalization after ocular onset in myasthenia gravis: a case series in Germany, J Neurol, 265, 2773, 10.1007/s00415-018-9056-8

Ding, 2020, Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in northwest China, BMC Neurol, 20, 238, 10.1186/s12883-020-01805-1

Wong, 2016, Ocular myasthenia gravis: toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification, J Neuroophthalmol, 36, 252, 10.1097/WNO.0000000000000350

Feng, 2020, Adult ocular myasthenia gravis conversion: a single-center retrospective analysis in China, Eur Neurol, 83, 182, 10.1159/000507853

Xu, 2020, Response to treatment in pediatric ocular myasthenia gravis, Muscle Nerve, 61, 226, 10.1002/mus.26745

Heckmann, 2018, A unique subphenotype of myasthenia gravis, Ann N Y Acad Sci, 1412, 14, 10.1111/nyas.13471

Roper, 2017, Myasthenia gravis and crisis: evaluation and management in the emergency department, J Emerg Med, 53, 843, 10.1016/j.jemermed.2017.06.009

Sanders, 2021, The Duke myasthenia gravis clinic registry: I—description and demographics, Muscle Nerve, 63, 209, 10.1002/mus.27120

Rodolico, 2016, Myasthenia gravis: unusual presentations and diagnostic pitfalls, J Neuromuscul Dis, 3, 413, 10.3233/JND-160148

Yang, 2019, Clinical features of laryngeal myasthenia gravis: a case series, Am J Otolaryngol, 40, 292, 10.1016/j.amjoto.2018.11.002

Ruiter, 2020, Fatigue in patients with myasthenia gravis: a systematic review of the literature, Neuromuscul Disord, 30, 631, 10.1016/j.nmd.2020.06.010

Farrugia, 2020, A practical approach to managing patients with myasthenia gravis: opinions and a review of the literature, Front Neurol, 11, 604, 10.3389/fneur.2020.00604

Dubey, 2020, Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum, Ann Neurol, 87, 659, 10.1002/ana.25708

Makarious, 2017, Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors, Eur J Cancer, 82, 128, 10.1016/j.ejca.2017.05.041

Fang, 2015, The autoimmune spectrum of myasthenia gravis: a Swedish population-based study, J Intern Med, 277, 594, 10.1111/joim.12310

Verwijst, 2021, Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: a Swedish nationwide register study, Eur J Neurol, 28, 1706, 10.1111/ene.14730

Muppidi, 2020, COVID-19-associated risks and effects in myasthenia gravis (CARE-MG), Lancet Neurol, 19, 970, 10.1016/S1474-4422(20)30413-0

Padda, 2018, Paraneoplastic syndromes and thymic malignancies: an examination of the international thymic malignancy interest group retrospective database, J Thorac Oncol, 13, 436, 10.1016/j.jtho.2017.11.118

Maggi, 2008, Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience, J Neuroimmunol, 201–202, 237, 10.1016/j.jneuroim.2008.07.012

Maddison, 2020, Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort, Sci Rep, 10, 10.1038/s41598-020-67571-9

Titulaer, 2008, Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome, J Clin Oncol, 26, 4276, 10.1200/JCO.2008.17.5133

Jovandaric, 2016, Neonatal outcome in pregnancies with autoimmune myasthenia gravis, Fetal Pediatr Pathol, 35, 167, 10.3109/15513815.2016.1164773

Santos, 2018, MuSK myasthenia gravis and pregnancy, Neuromuscul Disord, 28, 150, 10.1016/j.nmd.2017.11.014

Townsel, 2016, Seronegative maternal ocular myasthenia gravis and delayed transient neonatal myasthenia gravis, AJP Rep, 6, e133, 10.1055/s-0036-1579624

Hacohen, 2015, Fetal acetylcholine receptor inactivation syndrome: a myopathy due to maternal antibodies, Neurol Neuroimmunol Neuroinflamm, 2, e57, 10.1212/NXI.0000000000000057

Guptill, 2011, Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts, Muscle Nerve, 44, 36, 10.1002/mus.22006

Higuchi, 2011, Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis, Ann Neurol, 69, 418, 10.1002/ana.22312

Zhang, 2012, Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis, Arch Neurol, 69, 445, 10.1001/archneurol.2011.2393

Zoltowska, 2015, Collagen Q: a potential target for autoantibodies in myasthenia gravis, J Neurol Sci, 348, 241, 10.1016/j.jns.2014.12.015

Cortes-Vicente, 2016, Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin, JAMA Neurol, 73, 1099, 10.1001/jamaneurol.2016.2032

Rodriguez Cruz, 2015, Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis, JAMA Neurol, 72, 642, 10.1001/jamaneurol.2015.0203

Sabater, 2008, SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome, Neurology, 70, 924, 10.1212/01.wnl.0000281663.81079.24

Amandusson, 2017, Diagnostic utility of repetitive nerve stimulation in a large cohort of patients with myasthenia gravis, J Clin Neurophysiol, 34, 400, 10.1097/WNP.0000000000000398

Padua, 2014, Reliability of SFEMG in diagnosing myasthenia gravis: sensitivity and specificity calculated on 100 prospective cases, Clin Neurophysiol, 125, 1270, 10.1016/j.clinph.2013.11.005

Giannoccaro, 2020, Sensitivity and specificity of single-fibre EMG in the diagnosis of ocular myasthenia varies accordingly to clinical presentation, J Neurol, 267, 739, 10.1007/s00415-019-09631-3

Liik, 2016, Repetitive nerve stimulation often fails to detect abnormal decrement in acute severe generalized myasthenia gravis, Clin Neurophysiol, 127, 3480, 10.1016/j.clinph.2016.09.012

Punga, 2020, Botulinum toxin injections associated with suspected myasthenia gravis: an underappreciated cause of MG-like clinical presentation, Clin Neurophysiol Pract, 5, 46, 10.1016/j.cnp.2020.01.002

Nicholson, 1983, Comparison of diagnostic tests in myasthenia gravis, Clin Exp Neurol, 19, 45

Chatzistefanou, 2009, The ice pack test in the differential diagnosis of myasthenic diplopia, Ophthalmology, 116, 2236, 10.1016/j.ophtha.2009.04.039

Giannoccaro, 2020, Comparison of ice pack test and single-fiber EMG diagnostic accuracy in patients referred for myasthenic ptosis, Neurology, 95, e1800, 10.1212/WNL.0000000000010619

de Meel, 2020, Repetitive ocular vestibular evoked myogenic potentials in myasthenia gravis, Neurology, 94, e1693, 10.1212/WNL.0000000000009306

Valko, 2016, Ocular vestibular evoked myogenic potentials as a test for myasthenia gravis, Neurology, 86, 660, 10.1212/WNL.0000000000002383

Thomsen, 2020, Outcome measures in clinical trials of patients with myasthenia gravis, Front Neurol, 11, 10.3389/fneur.2020.596382

Barnett, 2018, Measuring clinical treatment response in myasthenia gravis, Neurol Clin, 36, 339, 10.1016/j.ncl.2018.01.006

de Meel, 2019, Sensitivity of MG-ADL for generalized weakness in myasthenia gravis, Eur J Neurol, 26, 947, 10.1111/ene.13867

Muppidi, 2017, Outcome measures in myasthenia gravis: incorporation into clinical practice, J Clin Neuromuscul Dis, 18, 135, 10.1097/CND.0000000000000156

Burns, 2016, The best of both worlds: Using patient-reported plus physician-scored measures during the evaluation of myasthenia gravis, Muscle Nerve, 53, 3, 10.1002/mus.24953

Romi, 2000, The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies, Arch Neurol, 57, 1596, 10.1001/archneur.57.11.1596

Baruca, 2016, Single fiber EMG as a prognostic tool in myasthenia gravis, Muscle Nerve, 54, 1034, 10.1002/mus.25174

Rakocevic, 2017, Single-fiber electromyography in the orbicularis oculi muscle in patients with ocular myasthenia gravis symptoms: does abnormal jitter predict response to treatment?, BMC Neurol, 17, 108, 10.1186/s12883-017-0891-5

Sussman, 2015, Myasthenia gravis: Association of British Neurologists' management guidelines, Pract Neurol, 15, 199, 10.1136/practneurol-2015-001126

Richards, 2017, Seronegative myasthenia gravis associated with malignant thymoma, Neuromuscul Disord, 27, 417, 10.1016/j.nmd.2017.01.023

Klimiec, 2018, Thymus imaging in myasthenia gravis: the relevance in clinical practice, Muscle Nerve, 58, 153, 10.1002/mus.26096

Priola, 2014, Imaging of thymus in myasthenia gravis: from thymic hyperplasia to thymic tumor, Clin Radiol, 69, e230, 10.1016/j.crad.2014.01.005

Maddison, 2020, Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome, J Neuroimmunol, 340, 10.1016/j.jneuroim.2020.577149

Keene, 2021, The feasibility of quantitative MRI of extra-ocular muscles in myasthenia gravis and Graves' orbitopathy, NMR Biomed, 34, 10.1002/nbm.4407

Europa, 2019, A review of the histopathological findings in myasthenia gravis: clues to the pathogenesis of treatment-resistance in extraocular muscles, Neuromuscul Disord, 29, 381, 10.1016/j.nmd.2019.03.009

Rautenbach, 2017, Extraocular muscle findings in myasthenia gravis associated treatment-resistant ophthalmoplegia, J Neuroophthalmol, 37, 414, 10.1097/WNO.0000000000000534

Punga, 2014, Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker, Ann Clin Transl Neurol, 1, 49, 10.1002/acn3.24

Punga, 2015, Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients, J Neurol Sci, 356, 90, 10.1016/j.jns.2015.06.019

Cron, 2019, Causes and consequences of miR-150-5p dysregulation in myasthenia gravis, Front Immunol, 10, 539, 10.3389/fimmu.2019.00539

Sabre, 2018, Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis, J Neuroimmunol, 321, 164, 10.1016/j.jneuroim.2018.05.003

Zhong, 2020, Low-dose rituximab lowers serum exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients, J Neuroimmunol, 348, 10.1016/j.jneuroim.2020.577383

Sabre, 2019, miR-30e-5p as predictor of generalization in ocular myasthenia gravis, Ann Clin Transl Neurol, 6, 243, 10.1002/acn3.692

Punga, 2016, Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis, J Neuroimmunol, 292, 21, 10.1016/j.jneuroim.2016.01.003

Wirtz, 2004, Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families, J Neurol, 251, 1255, 10.1007/s00415-004-0528-7

Renton, 2015, A genome-wide association study of myasthenia gravis, JAMA Neurol, 72, 396, 10.1001/jamaneurol.2014.4103

Niks, 2006, Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5, Neurology, 66, 1772, 10.1212/01.wnl.0000218159.79769.5c

Chen, 1993, Association of HLA-Bw46DR9 combination with juvenile myasthenia gravis in Chinese, J Neurol Neurosurg Psychiatry, 56, 382, 10.1136/jnnp.56.4.382

Matsuki, 1990, HLA antigens in Japanese patients with myasthenia gravis, J Clin Invest, 86, 392, 10.1172/JCI114724

Chuang, 2014, Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naive T cells, J Autoimmun, 52, 122, 10.1016/j.jaut.2013.12.006

Basta, 2018, Survival and mortality of adult-onset myasthenia gravis in the population of Belgrade, Serbia, Muscle Nerve, 58, 708, 10.1002/mus.26132

Hansen, 2016, Mortality in myasthenia gravis: a nationwide population-based follow-up study in Denmark, Muscle Nerve, 53, 73, 10.1002/mus.24697

Westerberg, 2020, Mortality rates and causes of death in Swedish myasthenia gravis patients, Neuromuscul Disord, 30, 815, 10.1016/j.nmd.2020.08.355

Lipka, 2020, Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome, Neurology, 94, e511, 10.1212/WNL.0000000000008747

Jeong, 2018, Factors associated with quality of life of people with myasthenia gravis, PLoS One, 13, 10.1371/journal.pone.0206754

Szczudlik, 2020, Determinants of quality of life in myasthenia gravis patients, Front Neurol, 11, 10.3389/fneur.2020.553626